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Clostridiodes difficile is a common cause of healthcare-associated 
diarrhoea. The clinical outcome depends on host factors and the 
virulence of the toxin-producing strain. This organism causes disease that 
ranges in severity from asymptomatic colonisation to severe diarrhoea, 
pseudomembranous colitis, toxic megacolon, colonic perforation and 
death.[1-3] The principal risk factor for C. difficile infection (CDI) is prior 
antibiotic therapy.[4]
Results of a systematic review assessing the epidemiology of CDI in 
low and middle Human Development Index countries show that there is 
a paucity of published literature describing the epidemiology and burden 
of CDI.[2] Rajabally et al.[1,3] highlight that data relating to the burden of 
C. difficile-associated disease (CDAD) in southern Africa are limited. 
The study conducted by this group emphasises that the magnitude of the 
CDI burden in South African (SA) hospitals is not known.[1,3]
Freeman et al.[5] note the two key issues that hinder understanding 
of the epidemiology of CDI. Firstly, there is poor recognition and 
documentation of CDAD.[5] The second obstacle is the many different 
approaches to the laboratory diagnosis of CDI. This is a dilemma also 
encountered in SA.[5] There are numerous targets and combinations 
of targets that can be used to detect C. difficile (cell cytotoxicity 
assays (CCAs), toxigenic culture, glutamate dehydrogenase (GDH), 
toxins through enzyme immunoassay (EIA), and toxin genes through 
polymerase chain reaction (PCR)). Researchers in the UK have 
noted a variation in the reference standards for CDI diagnosis. This 
variation gives rise to differences in assessment of the diagnostic 
performance of assays and contributes to uncertainty in diagnosing 
CDI.[6,7] It is therefore likely that the measured incidence of infection 
will vary according to the laboratory diagnostic method used.[5-7]
PCR-based testing is unable to differentiate between infection 
and colonisation. As a result, reliance on it as a stand-alone test 
may result in over-diagnosis of CDI.[3] The low sensitivity of toxin 
EIAs also makes these unsuitable as stand-alone tests.[3,6] For this 
reason, an algorithm that includes a sensitive assay (GDH or 
PCR) followed by a specific assay (toxin detection) may provide 
more accurate results.[8] The Society for Healthcare Epidemiology 
of America (SHEA), the Infectious Diseases Society of America 
(IDSA) and the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) all recommend the use of multistep 
algorithms for the diagnosis of CDI.[8,9] These algorithms allow 
reliable exclusion of CDI without additional tests if the GDH screen 
or PCR is negative,[8] reducing the turnaround time significantly 
while providing accurate results.[8,9]
Objectives
Prior to July 2016, the Charlotte Maxeke Johannesburg Academic 
Hospital (CMJAH) Microbiology Laboratory used stand-alone PCR 
and stand-alone toxin EIA for CDI diagnosis. Currently, a two-step 
algorithm for CDI diagnosis is used. A rapid EIA for GDH and toxin 
A/B is the initial test, followed by PCR on the subset of samples that 
are GDH-positive and toxin-negative. The primary objective of this 
study was to analyse the results yielded by the diagnostic methods 
used during the two periods and their impact on the reported rates 
of CDI. The secondary objective was to estimate the incidence of 
CDI in the overall patient population at CMJAH, as well as specific 
at-risk patient populations such as critical care, oncology, surgical 
and gastroenterology patients.
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Background. Clostridiodes difficile is a common cause of healthcare-associated diarrhoea. Laboratory testing for C. difficile infection (CDI) 
remains an area of confusion, as there is not a single accepted reference standard or a single best test.
Objectives. To analyse the impact of different diagnostic methods on reported CDI rates. In addition, CDI incidence rates at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH), Johannesburg, South Africa, were determined.
Methods. Results of stool samples submitted for C. difficile testing at CMJAH from 1 January 2014 to 31 August 2017 were reviewed. From 
January 2014 to July 2016, samples were tested by polymerase chain reaction (PCR) or toxin immunoassay, and from August 2016 to August 
2017, algorithm-based testing (glutamate dehydrogenase and toxin immunoassay followed by PCR) was performed.
Results. A total of 4 829 samples were submitted. For the first period, toxin immunoassay and PCR showed a positivity rate of 11.4% and 
21.1%, respectively, with an overall positivity rate of 18.7% (95% confidence interval (CI) 15.6 - 21.9). For the second period, the positivity 
rate was 15.9% (95% CI 11.3 - 17.7). This rate included samples that were GDH-positive and either showed toxin production or had a 
positive Xpert result. The CDI incidence for the two periods was different, with an incidence rate of 8.8 and 6.1 per 10 000 patient-days for 
the first and second periods, respectively.
Conclusions. The choice of laboratory testing method has a major impact on the diagnosis of CDI, and therefore on reported rates of CDI. 
Standardisation of laboratory testing and incidence rate reporting is required in order to obtain robust and reliable data.
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Methods
Design and setting
This was a retrospective descriptive study. CMJAH is a 1 088-bed 
tertiary hospital in Johannesburg. Results of stool samples submitted 
for C. difficile testing at CMJAH from 1 January 2014 to 31 August 
2017 were reviewed. Laboratory data were requested from the 
National Health Laboratory Service (NHLS) and Corporate Data 
Warehouse.
Microbiological testing
Formed stools were rejected by the laboratory. Samples with delayed 
transport to the laboratory (>2 hours post collection) were not 
rejected. During the period January 2014 - July 2016, laboratory 
testing for CDI was performed using two test methods. The test 
method used in each case was determined by when the sample was 
submitted. Samples that were collected during the regular working 
hours of 07h00 - 17h00 were analysed using PCR (Xpert C. difficile; 
Cepheid, USA). The test method used after hours, from 17h00 - 
07h00 and during weekends, was the EIA Immuno-Card Toxin A & 
B assay (Meridian Bioscience, USA).
Samples that tested either PCR-positive with Xpert C. difficile 
or toxin-positive with the Immuno-Card Toxin A & B assay were 
interpreted as positive for the purposes of analysis.
From 1 August 2016, a two-step algorithm was used for laboratory 
diagnosis of CDI. The C. Diff Quik Chek Complete (TechLab, USA) 
detects GDH as a screen for the presence of C. difficile. This assay also 
detects the presence of toxin A and B. A positive result for both the 
GDH and toxin indicates C. difficile disease. In contrast, a positive 
result for only the GDH component may indicate the presence of a 
non-toxin-producing strain. For samples that tested GDH-positive 
and toxin-negative, reflex PCR (Xpert C. difficile; Cepheid) testing 
was performed to detect the presence of toxin-encoding gene.
Data for epidemiology review were sorted according to the current 
reporting and interpretation standard operation procedure at the 
NHLS (unpublished data): (i) GDH-negative and toxin-negative: 
C. difficile not detected; (ii) GDH-positive and toxin-positive: toxin-
producing C. difficile detected; (iii) GDH-negative and toxin-positive: 
indeterminate results, repeat specimen to be submitted to the 
laboratory; and (iv) GDH-positive and toxin-negative: C. difficile 
antigen detected, toxin not detected. For the subset of samples that 
tested GDH-positive and toxin-negative following reflex PCR testing, 
data were also classified according to whether toxin-encoding genes 
were detected or not detected. 
Samples that tested GDH-positive and toxin-positive were referred 
to as ‘true positives’ for the purposes of analysis. True positives 
together with samples that tested GDH-positive, toxin-negative 
and PCR-positive were referred to as ‘all positives’. Samples with 
indeterminate results were excluded from the analysis.
Repeat samples within a 2-week period were excluded from the 
analysis.
Patient-days data for calculation of incidence rates were obtained 
from the hospital. The combined PCR-positive and EIA-positive 
results were used for calculation of the incidence rates for the January 
2014 - July 2016 period and ‘all positives’ for August 2016 - August 
2017.
Statistical analysis
The positivity rate for each diagnostic method was calculated by 
dividing the positive CDI results by the total number of samples over 
the relevant periods (January 2014 - July 2016 and August 2016 - 
August 2017).
The paediatric and adult patient-days for the relevant period were 
used as the denominator for the CDI incidence rate calculations.
Ninety-five percent confidence intervals (CIs) were determined for 
the incidence rates for the two periods.
Stata statistical software version 14 (StataCorp, USA) was used for 
the analysis.
Ethical considerations
The study was approved by the University of the Witwatersrand 
Human Research Ethics Committee (ref. no. M170941).
Results
A total of 650 samples tested positive from the 3 463 samples 
collected from January 2014 to July 2016 (EIA and PCR methods). 
The overall positivity rate was 18.8% (95% CI 15.6 - 21.9) (Table 1).
A total of 1 366 samples were submitted during the second test 
period and 217 were positive, with a positivity rate of 15.9% (95% 
CI 11.3 - 17.7). This rate included all the samples that were GDH-
positive and either showed toxin production (54%) or had a positive 
Xpert result (46%) (Table 1).
The incidence density of C. difficile infections was higher in the 
first test period (Table 2).
For the study period August 2016 - August 2017, the multi-
disciplinary intensive care unit (ICU) had the highest incidence of 
CDI at 46.1 per 10 000 patient-days. The second-highest incidence 
rate was seen in the trauma ICU, followed by the infectious disease 
unit, with rates of 29.1 and 27 per 10 000 patient-days, respectively 
(Fig. 1). For many of the units, a large proportion of the positive 
results were toxin-negative, Xpert-positive.
Paediatric medical and paediatric surgical units had an overall low 
incidence rate of 2.1 and 1 per 10 000 patient-days (Fig. 1).
Table 1. Impact of different laboratory testing strategies
Total positive 
samples, n
Total samples,  
N
Positivity rate,  
% (95% CI)
Testing period January 2014 - July 2016
Xpert 554 2 622 21.1 (19.5 - 23.1)
Meridian Immuno-Card 96 841 11.4 (10.8 - 12.2)
Total 650 3 463 18.8 (15.6 - 21.9)
Testing period August 2016 - August 2017
C. Diff Quik Chek Complete (GDH-positive , toxin-positive) 118 1 366 8.6 (7.9 - 9.2)
GDH-positive, toxin-negative and Xpert-positive 99 1 366 7.3 (6.9 - 7.9)
Total 217 1 366 15.9 (11.3 - 17.7)
CI = confidence interval.
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Discussion
The different laboratory testing strategies 
utilised by the CMJAH laboratory had a 
substantial impact on the reported CDI 
rates. In the first study period, stand-alone 
PCR-based testing yielded almost double the 
number of positive results compared with 
stand-alone toxin EIA testing. Similarly, in 
the second study period, reflex PCR-based 
testing of GDH-positive, toxin-negative 
samples almost doubled the number of 
positive results compared with GDH and 
toxin EIA testing alone. The difference in 
the laboratory testing methods and stand-
alone PCR testing specifically, for a large 
proportion of the samples in the first study 
period, probably contributed considerably 
to the higher CDI incidence rate for the first 
study period. The overall CDI incidence rate 
at CMJAH is comparable to endemic rates 
reported from other regions (Table 2).[10] 
Some hospital units had high CDI rates. 
However, a proportion of the positive results 
may reflect colonisation rather than CDAD.
Laboratory testing for CDI is a rapidly 
changing field. It is also an area of confusion, 
because there is not a single accepted 
reference standard or a single best test.[11] The 
usefulness of a CDI diagnostic test is judged 
on its sensitivity, specificity, turnaround time, 
cost and availability.[11] Toxigenic culture and 
CCA are regarded as the reference tests for 
the laboratory diagnosis of CDI.[6,8] However, 
these assays are not widely used owing to 
their long turnaround times and technical 
requirements.[12]
These assays also pose a challenge in 
clinical interpretation and diagnostic 
method validations, as they have different 
targets and are not directly comparable.[6,8] 
Planche et al.,[6] in a study that compares 
results of toxigenic culture and CCA with 
clinical outcomes, reported that the two 
reference tests provide different data. This 
study shows that a positive CCA result 
correlates with CDAD, whereas a positive 
toxigenic culture (with negative CCA) is 
more likely to indicate asymptomatic C. 
difficile colonisation.[6] In keeping with 
these findings, the ESCMID review of CDI 
diagnostics concluded that when toxin is not 
detected from a sample but toxigenic culture 
is positive, further evaluation is required to 
distinguish asymptomatic colonisation from 
true CDI.[8]
During the first study period, PCR-based 
testing (Xpert) yielded a higher positivity 
rate than toxin EIA testing. PCR-based 
testing has been shown to be rapid, but is 
criticised for showing suboptimal specificity 
for CDI diagnosis.[11,12] Increased CDI rates 
associated with PCR-based testing, compared 
with toxin detection-based diagnosis, have 
been reported in other studies.[6,12] In a study 
assessing the impact of diagnostic assay type 
on CDI and the associated complication 
rates, Longtin et al.[12] found that PCR alone 
was associated with a >50% increase in CDI 
incidence compared with algorithm-based 
testing.[12] PCR-based testing, like toxigenic 
culture, can have a low specificity, and hence 
a low positive predictive value (PPV), for 
CDI diagnosis and generally should not be 
used alone, but instead as part of a multistep 
algorithm.[6,8,9] However, in high-prevalence 
settings or in patients with a high pre-test 
probability of CDI, PCR will have a more 
favourable PPV for CDI.[6,13] The 2017 IDSA 
CDI guidelines support the use of stand-
alone PCR in patients with a high pre-test 
probability of CDI.[9]
Studies have shown that toxin EIA tests 
are less sensitive than PCR and results 
are variable owing to toxin degradation 
associated with delayed sample testing.[3] 
Delayed processing may have contributed 
to the lower positivity rate in the current 
study. In a study from the Western Cape, SA, 
researchers attributed a lower CDI burden 
to strain diversity and low levels of toxin 
Table 2. Incidence density of Clostridiodes difficile
Test period Total positive samples, n Total patient-days Incidence rate per 10 000 patient-days (95% CI)
January 2014 - July 2016 650 735 240 8.84 (8.17 - 9.55)
August 2016 - August 2017 217 357 871 6.06 (5.28 - 6.92)
CI = confidence interval.
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Fig. 1. Unit-specific Clostridiodes difficile incidence rate based on algorithm-based testing, August 
2016 - August 2017. (ICU = intensive care unit.)
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production.[3] In this study, the positivity rate of Xpert (21.13%) was 
almost double that of EIA (11.41%). Although toxin EIAs are rapid, 
widely available and inexpensive, they have poor sensitivity and are 
no longer recommended as stand-alone tests.[11]
In view of the increasing evidence that stand-alone assays for CDI 
diagnosis are suboptimal, the laboratory at CMJAH implemented a 
two-step algorithm in August 2016. Use of the two-step algorithm 
may have decreased the number of false-positive results and allowed 
for stratification of patients into those without CDI, those with CDI, 
and potential carriers for C. difficile.[6,8,9]
The majority of clinical laboratories do not use reference methods 
in multistep algorithms;[11] however, the use of diagnostic methods 
that have been validated using the reference methods is common. [8] 
Avila et al.[11] showed that the combined sensitivity of assays such 
as C. Diff Quik Chek (GDH and toxin detection in a single assay) 
ranges between 80% and 100%, and the specificity between 87% 
and 100%. [11] However, in such assays the sensitivity of the toxin 
component is not certain, and there is therefore a role for PCR-based 
testing of GDH-positive, toxin-negative samples.[8,9]
The positivity rate of samples that were tested by a second test 
(Xpert) in the two-step algorithm was 7.25%. The clinical relevance 
of samples that are GDH-positive, toxin-negative and PCR-positive 
is still not clear. The patient may have CDI with low toxin levels 
that are not detectable with the EIA used. Alternatively, the patient 
may simply be colonised with toxigenic C. difficile.[6,8] The decision 
whether to treat these patients should be based on the pre-test 
probability of CDI and clinical evaluation of the patients. Colonised 
patients do, however, play a role in transmission of infection, and 
implementation of contact precautions is indicated.[8,9]
It is difficult to interpret the incidence data from the first study 
period, as the testing methodology used was not uniform. The 
majority of CDI cases were identified by PCR, and this may have 
resulted in a falsely elevated rate. Almost half the positive results 
in the second study period were toxin-negative, Xpert-positive; the 
true CDI incidence for this period may therefore be lower than the 
reported 6.1 cases per 10 000 patient-days.
The incidence density of C. difficile was lower in the second study 
period compared with the first period. The testing rate in the two 
study periods differed (data not shown), and this may have had some 
impact on the incidence rates. However, CDI cases were defined 
using ESCMID- and IDSA-recommended algorithm-based testing 
during the second period, so the data are more robust than those 
of the first study period.[4] The difference in incidence between 
the study periods is probably largely due to the move to a testing 
methodology (algorithm-based testing) that has been shown to 
have an increased accuracy for CDI diagnosis.[12,13] Importantly, 
these results illustrate the need for uniform laboratory testing 
methodologies and surveillance definitions to promote reliable data 
generation, as well as improved interpretation and comparison of 
CDI incidence rates.
A CDI incidence rate of 5.3 per 10 000 patient-days was found in a 
meta-analysis from Asia, which was similar to that reported in Europe 
and North America and indicated by the results of this study. [10] Over 
the past few decades, there have been reports of widespread increases 
in the incidence and severity of and mortality associated with CDI. 
However, there is a paucity of SA data. Rajabally et al.[1] found that 
the incidence of CDI in their SA tertiary institution was much lower 
than that reported in the West.[1] However, limitations of their study 
include that stand-alone toxin EIA testing was performed. The 
findings of the current study provide some of the much-needed local 
data.[1,2]
Analysis of the incidence density of specific units showed the 
multidisciplinary ICU to have the highest incidence rate. Critically ill 
patients are at increased risk for CDI owing to multifactorial causes. 
Risk factors include the use of broad-spectrum antimicrobials, gastric 
acid suppression, advanced age, prolonged hospitalisation, enteral 
feeds, chronic kidney disease and deficient immune status, all of 
which are associated with the development of CDI.[1,3,14-17]
Other units showing particularly high CDI incidence rates 
were the trauma, infectious diseases and gastrointestinal surgical 
units. Incidence rates were also elevated in the medical oncology, 
gastroenterology/haematology, renal transplant and renal/nuclear 
medicine units. Each of these patient populations have well-
recognised risk factors for CDI.[18,19]
Paediatric units showed an overall low incidence density. C. diffi-
cile is generally non-pathogenic in infants.[20] CDI may occur in 
children aged 1 - 3 years, but other aetiologies, especially viral, are 
more common.[20] In older children, increasing CDI rates have been 
documented in some settings.[20,21]
This study has demonstrated that the overall reported CDI incidence 
rate decreased with the introduction of a two-step algorithm for 
laboratory diagnosis of CDI. Standardisation of laboratory testing 
methodology and CDI incidence rate reporting is required in order 
to yield robust data. Laboratories must incorporate detection of free 
toxin in their testing algorithms and clearly indicate on reports whether 
free toxin or toxigenic C. difficile has been detected. Clinicians must 
be cognisant of the difference in the implications of these two results.
Study strengths and limitations
Strengths of this study are that the results for a large number of 
samples were available for analysis, reducing potential bias towards 
any test method. During the first study period, all the samples were 
not tested by both PCR and toxin EIA; however, sample allocation 
to a particular method was based only on the time of sample 
receipt in the laboratory. In the second study period, the testing 
algorithm used was in alignment with international guidelines and 
recommendations. Similarly, the calculation of CDI incidence rates 
was based on recognised surveillance definitions.
The study is limited by its retrospective design, with potential 
to introduce bias. Our practice was restricted to the use of specific 
commercially available kits to perform EIA and PCR testing. The 
testing rate in the two study periods was not uniform, and definitive 
conclusions regarding the difference in the incidence rates therefore 
cannot be made. The clinical significance of GDH-positive, toxin-
negative and PCR-positive results requires further elucidation. It 
is difficult to assess the magnitude of the overestimation of CDI 
rates related to PCR testing in both study periods. The study was 
conducted at a single centre, and caution should therefore be 
exercised in extrapolating these data to other settings.
Conclusions
C. difficile is a major cause of healthcare-associated diarrhoea. Labora-
tory diagnostics are important to differentiate CDI from other causes 
of diarrhoea and to establish the presence of infection v. colonisation. 
The choice of laboratory testing method(s) has a major impact on the 
diagnosis of CDI, and hence on the reported rates of CDI.
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